Printed From BioPortfolio.com

AbbVie, Bristol-Myers to evaluate ABBV-399/Opdivo regimen in advanced solid tumors

04:06 EDT 25 Sep 2017 | Pharmaceutical Business Review

AbbVie will evaluate its investigational antibody drug conjugate, ABBV-399 (telisotuzumab vedotin), in combination with Bristol-Myers Squibb’s immunotheraphy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

Original Article: AbbVie, Bristol-Myers to evaluate ABBV-399/Opdivo regimen in advanced solid tumors

Give dad the gift of knowledge. Order his DNA Ancestry kit this Father's Day for $99 at 23andMe! Ord

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

Topics

AbbVie, Bristol-Myers to evaluate ABBV-399/Opdivo regimen in advanced solid tumors

More From BioPortfolio on "AbbVie, Bristol-Myers to evaluate ABBV-399/Opdivo regimen in advanced solid tumors"

Relevant Topics

News Quicklinks